echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > FDA approves dual-targeted type 2 diabetes drug Mounjaro, which can help non-diabetic patients lose 22.5%!

    FDA approves dual-targeted type 2 diabetes drug Mounjaro, which can help non-diabetic patients lose 22.5%!

    • Last Update: 2022-08-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The FDA approved Eli Lilly's once-weekly dual GIP and GLP-1 receptor agonist Mounjaro (tirzepatide) to improve glycemic control in adults with type 2 diabet.


    Three different doses of treatment were evaluated in the Phase III SURPASS program involving more than 20,000 patients with type 2 diabetes in 10 clinical trials, five of which were global registry studi.


    On average, patients randomized to receive Mounjaro 15mg (the maximum recommended dose) successfully reduced their HbA1c levels by 6% when used alone and by 5% compared to placebo when used with the long-acting dr.


    Mounjaro is also being evaluated in six clinical trials for the treatment of obesi.


    Eli Lilly recently reported results from the SURMOUNT-1 study, showing that the drug helped patients without type 2 diabetes lose up to 25% of their body weig.


     

    Original source:

    Original source:

    https://firstwordphar.


    https://firstwordphar.
    com/story/5571833Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.